Brief: Ngm Bio Announces Topline Results From The Catalina Phase 2 Trial Of Ngm621 In Patients With Geographic Atrophy (Ga) Secondary To Age-Related Macular Degeneration
17/10/2022 12:55
NGM Biopharmaceuticals Inc NGM.O :
* NGM BIO ANNOUNCES TOPLINE RESULTS FROM THE CATALINA PHASE
2
TRIAL OF NGM621 IN PATIENTS WITH GEOGRAPHIC ATROPHY (GA)
SECONDARY TO AGE-RELATED MACULAR DEGENERATION
* NGM BIOPHARMACEUTICALS INC - TRIAL DID NOT MEET PRIMARY
ENDPOINT
* NGM BIOPHARMACEUTICALS - NGM621 SHOWED FAVORABLE SAFETY
AND
TOLERABILITY, WITH NO EVIDENCE OF INCREASED CNV CONVERSION AND
NO TREATMENT-RELATED SAES
* NGM BIOPHARMACEUTICALS INC - CONTINUE TO EVALUATE VARIOUS
PRE-SPECIFIED SECONDARY ENDPOINTS AND POST-HOC ANALYSES
Source text for Eikon: ID:nGNX6mzkVh
Further company coverage: NGM.O
Recent news on NGM Biopharmaceuticals
See all newsBrief: NGM Biopharmaceuticals Q4 Net Income USD -27.67 Million
Brief: NGM Bio Enters into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group
NGM Biopharmaceuticals Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Ngm Biopharmaceuticals Says It Got Written Notice From Nasdaq Informing It Has Regained Compliance With Nasdaq Listing
Brief: NGM Bio Announces New Clinical Data From Ongoing Trial Of Ngm707 In Advanced Solid Tumors